连接内的同时有效性,以量化健康年轻人单步启动的时间参数
Laure Coudrat1, Jean-Luc Kop2, Joseph Bascou3
1Université de Toulon, J-AP2S, Campus de La Garde, Toulon, France; Université de Lorraine, 2LPN, UR 7489, 91 avenue de la libération, BP 3142, 54021 Nancy cedex, France.
Journal of biomechanics
|April 18, 2025
概括
连接的内可靠地测量健康成年人的单步启动阶段. 这种可穿戴技术与强力板进行验证,显示了评估不同人群的步态的潜力,包括老年人和患有神经障碍的人.
科学领域:
- 生物力学 生物力学
- 可穿戴技术可穿戴技术
- 运动科学 运动科学
背景情况:
- 步行和单步启动通常使用实验室强力板进行测量.
- 像惯性测量单元一样,可穿戴式传感器正在被验证用于运动分析.
- 连接的内提供了一种更简单的方法来检测运动阶段,但它们在步行启动测量中的使用没有得到验证.
研究的目的:
- 为了验证连接的内用于测量单步启动的时间相.
- 为了评估相连的内的可靠性与黄金标准的强力板相比.
- 为了研究运动速度对连接插件的精度的影响.
主要方法:
- 14名健康的年轻人穿着连接的内并站在强力板上,以各种速度进行单步启动.
- 开发了一个定制的算法来识别运动事件并测量三个阶段:预期的姿势调整,执行和总启动.
- 协同相关系数 (CCC) 和布兰德-阿尔特曼图表被用来比较内和强力板.
主要成果:
- 所有测量阶段的CCC平均值为0.81 (范围[0.71-0.89]),超过了0.68.8的可接受度值.
- 连接的内的准确性仅受到指示的移动速度的微小影响.
- 开发的算法与力板测量结果有很高的一致性.
结论:
- 连接的内,当与开发的算法一起使用时,提供了一种可靠的方法来测量健康年轻人的单步启动阶段.
- 速度的最小影响表明,对于步行速度减弱的人群,如老年人或患有神经疾病的人群,其潜在适用性.
- 这项技术为在专业实验室环境之外进行生态步态分析提供了一个有希望的,易于使用的工具.
相关概念视频
00:54Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters
The noncompartmental approach is a widely used method in pharmacokinetics to assess drugs' behaviors in the body. It considers several factors, including clearance, bioavailability, and total volume of distribution.
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's overall...
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's overall...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
01:23Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.